The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein
Open accessAbstract
Aims: The aims of this observational study were to assess the variability in imatinib pharmacokinetics and to explore the relationship between its disposition and various biological covariates, especially plasma α 1‐acid glycoprotein concentrations. Methods: A population pharmacokinetic analysis was performed using NONMEM based on 321 plasma samples from 59 patients with either chronic myeloid leukaemia or gastrointestinal stromal tumours. The influence of covariates on oral clearance and volume of distribution was examined. Furthermore, the in vivo intracellular pharmacokinetics of imatinib was explored in five patients. Results: A one‐compartment model with first‐order absorption appropriately described the data, giving a mean (± SEM) oral clearance of 14.3 l h−1 (± 1.0) and a volume of distribution of 347 l (± 62). Oral clearance was influenced by body weight, age, sex and disease diagnosis. A large proportion of the interindividual variability (36% of clearance and 63% of volume of distribution) remained unexplained by these demographic covariates. Plasma α 1‐acid glycoprotein concentrations had a marked influence on total imatinib concentrations. Moreover, we observed an intra/extracellular ratio of 8, suggesting substantial uptake of the drug into the target cells. Conclusion: Because of the high pharmacokinetic variability of imatinib and the reported relationships between its plasma concentration and efficacy and toxicity, the usefulness of therapeutic drug monitoring as an aid to optimizing therapy should be further investigated. Ideally, such an approach should take account of either circulating α 1‐acid glycoprotein concentrations or free imatinib concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Cited by
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
Demetri, G. D., Wang, Y., Wehrle, E., Racine, A., Nikolova, Z., Blanke, C. D., Joensuu, H., & von Mehren, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4818 · Cited by 401
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 296
Self-citationCortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3724 · Cited by 284
Metadata
- Authors
- Widmer, N., Decosterd, L. A., Csajka, C., Leyvraz, S., Duchosal, M. A., Rosselet, A., Rochat, B., Eap, C. B., Henry, H., Biollaz, J., & Buclin, T.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2006-06-23
- Volume
- 62
- Issue
- 1
- Pages
- 97-112
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2140111850
- Cited by
- 196
- References
- 1
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.